Best practices in contemporary diagnostic immunohistochemistry: panel approach to hematolymphoid proliferations.
Abstract: Context.--The complexities of diagnostic hematopathology in the modern era are well known, and even in this molecular era, immunophenotypic studies, together with routine histopathology, remain a critical component in the evaluation of many lymphoid proliferations. With numerous antibodies that can be used on routinely fixed, paraffin-embedded tissue sections, immunohistochemistry has become increasingly valuable. It then becomes a challenge knowing the best approach to the selection of antibodies to use and how to interpret them.

Objective.--To present a pragmatic immunohistochemical approach to the evaluation of lymphoid proliferations that stresses the utility of 2 limited panels to deal with the most commonly encountered lymphomas.

Data Sources.--English-language literature published between 1990 and 2008.

Conclusions.--A relatively limited panel of immunohistochemical stains may be used to diagnose and subclassify many of the more common lymphomas, although some cases will require additional stains and others fewer, depending on the case complexity. Immunohistochemical stains must always be interpreted in the context of the histopathologic and other ancillary studies.
Article Type: Report
Subject: Immunohistochemistry (Usage)
Immunohistochemistry (Analysis)
Lymphoproliferative disorders (Physiological aspects)
Lymphoproliferative disorders (Diagnosis)
Gene expression (Research)
Gene expression (Physiological aspects)
Pathology (Practice)
Lymph nodes (Biopsy)
Lymph nodes (Usage)
Authors: Garcia, Christine F.
Swerdlow, Steven H.
Pub Date: 05/01/2009
Publication: Name: Archives of Pathology & Laboratory Medicine Publisher: College of American Pathologists Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 College of American Pathologists ISSN: 1543-2165
Issue: Date: May, 2009 Source Volume: 133 Source Issue: 5
Topic: Event Code: 350 Product standards, safety, & recalls; 310 Science & research; 200 Management dynamics
Organization: Organization: World Health Organization
Accession Number: 230151997
Full Text: Immunohistochemical (IHC) stains have become a critical aid in diagnostic decision making when evaluating many lymph node biopsies or extranodal hematopoietic/ lymphoid infiltrates, particularly if flow cytometric studies have not been performed (and sometimes even if they have). However, knowing which stains to use and how to interpret them can be a challenge. This discussion provides a basic approach to this topic but is not an attempt to provide another detailed review of lymphoid immunophenotypic studies, as was published recently in this journal, nor does it aim to provide the type of diagnostic criteria well summarized in the World Health Organization monograph on tumors of the hematopoietic and lymphoid tissues. (1) Furthermore, it will not deal with the relative attributes of flow cytometry versus paraffin section immunostains, nor the contribution of molecular or cyto genetic studies. In addition, it does not aim to be comprehensive in covering the workup of all types of lymphoid neoplasms. Specifically, it does aim to first clarify the goals of performing IHC stains in the evaluation of lymphoid proliferations and then provide a pragmatic approach to how limited IHC panels, with potential additional follow-up stains, can help us recognize and classify some of the more common lymphomas. Finally, it should be clear that the intention is not to suggest that every case should be handled in an identical fashion--some cases may need less of a workup than an average case, and others more of a workup.

REASONS TO USE DIRECTED IHC PANELS IN THE EVALUATION OF LYMPHOID PROLIFERATIONS

One of the major purposes of paraffin section IHC panels is to serve as an aid in making a series of diagnostic decisions when lymph node biopsies or hematopoietic/ lymphoid infiltrates at extranodal sites are evaluated. Those decisions include determining whether a proliferation is benign or malignant; if malignant, whether it is a lymphoma; if a lymphoma, whether it is of Hodgkin or non-Hodgkin type; and then what precise type of Hodgkin or non-Hodgkin lymphoma. The stains are used to provide information that is not morphologically apparent, such as whether plasma cell populations are light chain class restricted; they are used to draw our attention to subtle morphologic features that otherwise might be missed, such as identifying small foci of lymphoma in otherwise hyperplastic lymph nodes; and in helping to identify the increasingly recognized "early" or "in situ" involvement of lymph nodes by mantle cell lymphoma (MCL) or follicular lymphoma. (2,3) Finally--and from our perspective, equally important--they function as an internal "private" quality control by either helping confirm our histologic impressions or letting us know (in the privacy of our own offices) that we had better rethink our original appraisal of a case. Even if one thinks the routine stained sections are obvious, there will be cases where even the most sophisticated experts may be fooled.

To accomplish the above goals, it is important to use relatively comprehensive panels of IHC stains, because individual stains or an extremely focused panel may be misleading. For example, doing a CD20, CD3, and BCL2 stain just to confirm a diagnosis of follicular lymphoma could be misleading if, in fact, one had a very follicular-appearing MCL, because one would have BCL2-positive follicles in both situations. On the other hand, indiscriminate use of IHC stains where one uses every stain in one's armamentarium is also not advised. Aside from the added expense and an open invitation for greater outside interference in the practice of pathology, use of large nondirected antibody panels can be misleading because they increase the chance of misinterpreting a finding that otherwise would not have been detected. This may occur because of an unusual immunoreactivity, an artifactual positive or negative staining pattern, or unfamiliarity with the expected staining pattern.

IHC PANELS IN DIAGNOSTIC HEMATOPATHOLOGY

Two IHC panels will be discussed, together with additional IHC stains that may be added in selected circumstances. The bulk of our discussion will cover a panel whose major purpose is to evaluate potential B-cell neoplasms (Table 1). However, although not covered here because of space constraints, the panel can also provide important clues as to the presence of a T-cell ([CD3.sup.+], [CD5.sup.+]), natural killer cell ([CD3.sup.+], [CD5.sup.-]), or even Hodgkin lymphoma. A basic and expanded panel to use in cases of suspected Hodgkin lymphoma will be discussed briefly (Table 2). These 2 panels can be used as part of the workup for most malignant lymphomas in the United States.4,5 Even more limited screening panels may be used in some circumstances, or sometimes none at all, depending on the histopathologic differential diagnosis, the degree of clinical suspicion, and the comfort level of the pathologist.

MULTIPURPOSE PANEL FOR THE EVALUATION OF SUSPECTED NON-HODGKIN LYMPHOMAS

The most widely used panel in our practice and the way in which we use it is described in Table 1.6,7 It will help resolve many cases of suspected B-cell lymphomas and provide clues to the diagnosis of T/natural killer cell or Hodgkin lymphomas. It is important to know not only the basic reactivity of each antibody but also what to look for that suggests the presence of a neoplasm and, if a lymphoma is recognized, how to use the findings to help with the precise classification. Likewise, the stains should be interpreted with attention not only to simple extent of positivity, but also to the architectural distribution and cytology of the positive (and negative) cells.

It should be noted that we do not routinely perform k and X stains on our paraffin-embedded sections because in our laboratory and many (but not all) other laboratories, these stains fail to reveal specific surface immunoglobulin staining in most cases. Most B-cell lymphomas have surface rather than significant amounts of cytoplasmic immunoglobulin expression, and so often the stains only show bothersome nonspecific staining or highlight a re active plasma cell population. In situ hybridization stains for [kappa] and [lambda] may deal with the nonspecific staining problems but do not provide significantly greater sensitivity. Detection of surface k and X expression is one of the major strengths of flow cytometric immunophenotypic studies. Nevertheless, paraffin section IHC stains for [kappa], [lambda],and sometimes the immunoglobulin heavy chains are useful in evaluating potential lymphoid or plasmacytic neoplasms, especially if there is plasmacytoid differentiation or overt plasma cells. We tend to add [kappa] and [lambda] stains when evaluating potential marginal zone lymphomas, because they often fail to have an "aberrant" B-cell phenotype, and a moderate number (based on the site and type) may have plasmacytic differentiation. Remember, however, that light-chain class restriction is not an absolute indicator of neoplasia!

HOW DO WE USE THE PANEL TO SUPPORT THE PRESENCE OF A LYMPHOID NEOPLASM?

Some of the more common ways in which the basic IHC panel can be used to support the presence of a lymphoid neoplasm are described below.

1. Identify BCL2-positive follicular center B cells, because most normal follicular center cells are BCL2 negative (Figure 1). One does need to beware of "positive" nodules of normal BCL2-positive, non-follicular center B cells (eg, primary follicles or BCL2-positive mantle zones cut tangentially; Figure 2) or follicles with numerous T cells. One must also remember that follicles colonized by non-follicular type lymphomas can also be BCL2 positive.

2. Identify areas with CD5 coexpression on B cells based on a comparison of the CD3, CD5, and CD20 stains. Whereas small populations of [CD5.sup.+] B cells are routinely seen by flow cytometry in normal individuals, recognizable areas where [CD5.sup.+] B cells aggregate are usually not identified in paraffin sections (Figure 3). We do occasionally see some expression in normal mantle zones. Interpretation may be complicated in cases with numerous T cells.

3. Identify sheets of B cells where there should not be sheets of B cells (Figure 4). This is most useful at extranodal sites, but you must beware of B-cell-rich reactive infiltrates that have been described in the breast. (8) Lymph

nodes may also have numerous interfollicular B cells in perisinus and medullary areas. Because of the sometimes prominent perisinus B-cell populations, reactive lymph nodes cut tangential to the capsule may also demonstrate apparent sheets of B cells.

4. Identify numerous CD10+ or [BCL6.sup.+] cells outside of follicular centers (Figure 5). Normally, only scattered [CD10.sup.+] cells of B-cell or T-cell origin can be seen, in addition to [CD10.sup.+] neutrophils. Sometimes one even sees some scattered [CD10.sup.+] lymphoblasts. Likewise, one normally expects to see only scattered [BCL6.sup.+] interfollicular lymphoid cells. It should also be kept in mind that not all neoplastic CD10 or [BCL6.sup.+] cells outside of follicles are necessarily related to follicular center cells. Other lymphomas can also express these antigens, including some lymphoblastic lymphomas and some T-cell lymphomas, such as angioimmunoblastic T-cell lymphoma.

5. Identify numerous [CD43.sup.+] B cells in a fashion analogous to identifying [CD5.sup.+] B cells. CD43 will help identify a distinct but overlapping population of normal and neoplastic B cells compared with CD5, and thus provides additional information, because sheets of [CD43.sup.+] B cells are not seen in most nonneoplastic circumstances. However, nonneoplastic [CD43.sup.+] B-cell populations can be identified in paraffin sections in some circumstances, such as in subepithelial regions of the tonsils, myo/lymphoepithelial sialoadenitis, atypical marginal zone hyperplasia, as described in children, (9) and in reactive lesions of the terminal ileum (including Peyer patches). (10) CD43 expression may be difficult to evaluate because of normal reactivity of background nonneoplastic T cells and plasma cells.

6. Identify significant populations of cyclin D1-positive lymphocytes or plasma cells. Because these cell types do not normally express cyclin D1, this strongly supports the presence of a neoplasm, usually of mantle cell or plasma cell myeloma type, although rare other B-cell neoplasms (such as hairy cell leukemia) and some carcinomas may also exhibit cyclin D1 positivity. Careful examination for internal control positivity is important because lack of cyclin D1 expression may sometimes be partly due to technical factors. (8) It is also important not to interpret nonlymphoid cell staining as abnormal (Figure 6).

[FIGURE 1 OMITTED]

[FIGURE 2 OMITTED]

HOW DO WE USE THE PANEL TO HELP CLASSIFY THE MORE COMMON B-CELL LYMPHOMAS?

Use of a phenotypic algorithm based on many of the antibodies included in this panel is a critical aid in the recognition and confident classification of many of the B-cell lymphomas (Figure 7). However, exceptions to the standard phenotypes occur not infrequently, and this schema should only be used as a general guideline.

Once one is dealing with a B-cell neoplasm, one can think of those that are usually [CD5.sup.+] and those usually [CD5.sup.-]. Most [CD5.sup.+] B-cell lymphomas are of chronic lymphocytic leukemia/small lymphocytic lymphoma or MCL type, with a minority of diffuse large B-cell lymphomas (DLBCLs) falling into this category, as well as occasional other B-cell neoplasms. Rare cyclin D1-negative MCLs are reported11; however, most are positive, (12) distinguishing them from chronic lymphocytic leukemia/small lymphocytic lymphoma in which, with possible rare exception, cyclin D1 is negative or only positive in proliferation centers. (13) CD23 expression, which can be detected in paraffin sections, is not a specific finding but also would favor the diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma over MCL. The CD5-negative B-cell lymphomas are next thought of in terms of those that are CD10 positive or negative. The former group, which also is usually BCL6 positive, includes most follicular lymphomas, some DLBCLs, and Burkitt lymphomas (BL; see below). The CD10-negative cases, which also are BCL6 negative, include the different types of marginal zone lymphoma, lymphoplasmacytic lymphoma, some DLBCLs, a minority of MCLs, and even some chronic lymphocytic leukemia/small lymphocytic lymphoma. Finally, there are [CD10.sup.+] [BCL6.sup.+] lymphomas, which mostly include DLBCLs, some follicular lymphomas, and particularly the diffuse cases of primary cutaneous follicle center lymphomas. (14) Bcell lymphomas of lymphoblastic origin may lack CD20 expression and can be found in the CD5-negative, CD10positive or CD10-negative groups. They usually also would express TdT.

Addition of a Ki-67 stain can also be useful in a number of circumstances, although precise agreed-upon rules for its interpretation in varied situations remain elusive, and it is one of the antibodies where reproducibility is an issue. The stain is probably most useful when there is suboptimal cytologic preservation, such as in many needlecore biopsies, in part because the nuclear morphologic fea tures are often better appreciated. What appears to be a diffuse proliferation of small lymphoid cells can turn into a large cell proliferation when one sees that the nuclei actually are larger than they appeared in the hematoxylineosin-stained section and that they have more vesicular chromatin and nucleoli. Remember, however, that Ki-67 will also be positive in some nontransformed small lymphoid cells that are cycling. Nevertheless, it can serve as another form of internal quality assurance, because if one was contemplating diagnosing chronic lymphocytic leukemia/small lymphocytic lymphoma and the Ki-67 stain shows sheets of positive nuclei throughout, one might want to carefully reexamine the histopathologic and other ancillary findings before rendering a diagnosis. In addition to improving cytologic detail in some cases, Ki-67 stains may be of value in assessing follicular lymphomas, as cases with an average proportion of Ki-67-positive intrafollicular cells of greater than 30% have been reported to be associated with a course more like that seen with grade 3 cases, even if histologically the lymphoma is of grades 1 to 2. (15) Prospective studies further evaluating this finding, however, are needed, and it must be remembered that there are also many grade 3 follicular lymphomas reported in some studies with less than 30% Ki-67-positive cells. (16) Ki-67 staining also has been used in the prognostication of MCLs, with varied cutoffs for what should be considered high (>60%, >40%, or even lower cutoffs).1 Its use in the differential diagnosis between BL and DLBCL is discussed below.

[FIGURE 3 OMITTED]

Much of the above discussion focuses on the small B-cell lymphomas. In contrast to many of the small B-cell neoplasms, where identification of a definite neoplasm can be a major challenge, many of the large cell, blastoid, and other transformed-appearing neoplasms are obviously neoplastic, and the goal of the immunostains is limited more to assessing the precise cell type present. As discussed above, the panel will identify the blastoid MCL. It is important to add a TdT and sometimes other markers of immaturity (eg, CD34 or, in T-cell proliferations, CD1a) when a truly blastic neoplasm is in the differential. It may also be necessary to add additional pan-B-cell markers, such as PAX-5 or CD22, and other pan-T-cell markers to establish the lineage of some lymphoblastic neoplasms. The sometimes very problematic distinction of DLBCL from BL is beyond the scope of our discussion here, but the presence of BCL2 expression that would be identified by our panel is a major strike against the latter diagnosis. (17-20) One could then add a Ki-67 stain looking for nearly 100% positivity to support the diagnosis of a BL, although the finding is not specific and may be found in some DLBLCs. Cytogenetic fluorescence in situ hybridization studies looking for MYC, BCL2, and BCL6 translocations can also be very helpful in these circumstances, but it must be remembered that MYC translocations are not specific for BL. (21-23) With the addition of a MUM-1 antibody, this panel will also provide the information needed to use the Hans algorithm for the distinction of DLBCLs of germinal center from those of non-germinal center type. (24) Whether this algorithm is of prognostic utility in the immunochemotherapy era or is the best of the available algorithms to accomplish this purpose is also beyond the scope of this manuscript. Furthermore, reproducibility is another major problem with immunophenotypic prognos tication of DLBCL.25 Our panel will not be sufficient for plasma cell or plasmablastic neoplasms that will require markers, such as CD138 (which identifies plasma cells but also some epithelial cells) and kappa and lambda stains. We also have not discussed the CD20-negative potential B-cell neoplasms that are best evaluated using one or more of the other pan-B-cell markers, such as PAX-5, CD79a, or CD22. (26)

[FIGURES 4-5 OMITTED]

[FIGURE 6 OMITTED]

Although we have dropped the use of an antibody to CD43 from our large cell panel because it does not generally help in the differential diagnosis of these usually overt neoplasms, it should be remembered that CD43 expression is found not only in many B- and T-cell lymphomas but also in many myeloid sarcomas. Other antibodies useful to help evaluate potential myeloid sarcomas include CD34 (blasts) and CD117 (immature myeloids, including myeloblasts plus some lymphoblasts), and the myeloid/ monocytic-associated markers, such as myeloperoxidase, CD33, lysozyme, neutrophil elastase, CD68 (PGM1 clone more specific for monocytic differentiation than KP-1), CD14, and CD163 (relatively specific monocytic marker).

PANEL FOR SUSPECTED HODGKIN LYMPHOMA

A basic panel for evaluating cases of potential Hodgkin lymphoma will be sufficient in most cases (Table 2). One should be aware that some Hodgkin lymphoma cases will have an "atypical" phenotypes that one may find, for example, absence of CD15 expression. Not all hematopathologists find the CD45 stain to be as useful as others. In problematic cases, depending on which features are causing confusion, one or more additional markers may be used. It is important to realize, however, that some cases will ultimately best be classified as a gray-zone lymphoma with features intermediate between DLBCL and Hodgkin lymphoma. (1,27) PAX-5, the pan-B-cell marker, can be used if the problem is a differential diagnosis with a T-cell neoplasm because most Reed-Sternberg cells are weakly positive. (28-30) If an EMA+, CD15", PAX5- population is identified, ALK staining is recommended to help exclude an anaplastic large cell lymphoma, which may morphologically mimic classical Hodgkin lymphoma.31 Remember that some T-cell neoplasms may include a population of large B cells. IRF4 MUM-1 is an excellent marker expected to be strongly positive in Reed-Sternberg cells and can be used to highlight their presence, even though it is not at all specific and is also present in anaplastic large cell lymphoma. (30) In the differential diagnosis with DLBCL, Oct2 and Bob.1 stains can be used because the Reed-Sternberg cells in most cases of classical Hodgkin lymphoma should be negative for one or both of these antigens, and DLBCL should be positive with both. (28,32,33) Difficulties with a differential diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and a T-cell/histiocyte-rich large B-cell lymphoma can sometimes be dealt with by adding a CD21 stain to identify the follicular nodules that are characteristic of NLPHL, a J-chain stain that helps in some cases to identify the neoplastic cells in NLPHL, and a CD57 stain that in most cases of NLPHL identifies numerous positive cells, sometimes forming rosettes around the neoplastic cells. Recently, the utility of a PD-1 stain to identify T-cell rosettes in NLPHL has been reported. (49) Sometimes a BCL6 stain that identifies the neoplastic cells in NLPHL may also be helpful, although it is very nonspecific.

[FIGURE 7 OMITTED]

SUMMARY

We have seen how the use of a relatively limited panel of IHC stains can help deal with many of the more common neoplastic hematopathologic diagnoses (Table 3). Nevertheless, some cases will require additional stains (Table 4), and others fewer. Cytogenetic and/or molecular studies also may be critical in some cases. The complexity of the cases you are dealing with will affect the number of immunostains you need to perform and the need for additional ancillary studies. Finally, remember that IHC stains always must be put into the context of the histopathologic studies and the other ancillary studies that have been performed.

References

(1.) Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.

(2.) Cong P, Raffeld M, Teruya-Feldstein J, Sorbara L, Pittaluga S, Jaffe ES. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood. 2002;99:3376-3382.

(3.) Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol. 2003;34:1030-1034.

(4.) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.

(5.) Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.

(6.) King BE, Chen C, Locker J, etal. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. ModPathol. 2000;13:1219-1231.

(7.) Chen CC, Raikow RB, Sonmez-Alpan E, Swerdlow SH. Classification of small B-cell lymphoid neoplasms using a paraffin section immunohistochemical panel. Appl /mmunohistochem Mol Morphol. 2000;8:1-11.

(8.) Boudova L, Kazakov DV, Sima R, et al. Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients. Am J Dermatopathol. 2005;27:375-386.

(9.) Attygalle AD, Liu H, Shirali S, et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood. 2004;104:3343-3348.

(10.) Lee PS, Beneck D, Weisberger J, Gorczyca W. Coexpression of CD43 by benign B cells in the terminal ileum. Appl /mmunohistochem MolMorphol. 2005; 13:138-141.

(11.) Fu K, Weisenburger DD, Greiner TC, etal. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315-4321.

(12.) Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33: 7-20.

(13.) O'Malley DP, Vance GH, Orazi A. Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin d1 expression: a potential diagnostic pitfall. Arch Pathol Lab Med. 2005;129:92-95.

(14.) Pimpinelli N, Berti E, Burg G, et al. Cutaneous follicle centre lymphoma. In: LeBoit PE, Burg G, Weedon D, Sarasin A, eds. Pathology & Genetics: Skin Tumours. Lyon, France: IARC Press; 2006:196-197. World Health Organization Classification of Tumours.

(15.) Wang SA, Wang L, Hochberg EP, Muzikansky A, Harris NL, Hasserjian RP. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am JSurgPathol. 2005;29:1490-1496.

(16.) Zhang K, Prichard JW, Yoder S, De J, Lin F. Utility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysis. Hum Pathol. 2007;38:878-882.

(17.) Cogliatti SB, Novak U, Henz S, Schmid U, Moller P, Barth TF. Diagnosis of Burkitt lymphoma in due time: a practical approach. BrJHaematol. 2006;134: 294-301.

(18.) Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lym phoma. N Engl JMed. 2006;354:2431-2442.

(19.) Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354: 2419-2430.

(20.) Stein H, Hummel M. Histopathology in the light of molecular profiling. Ann Oncol. 2006;17(suppl 4):iv5-iv7.

(21.) Haralambieva E, Boerma EJ, van Imhoff GW, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am JSurgPathol. 2005;29:1086-1094.

(22.) Ferry JA. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006;11:375-383.

(23.) Akasaka T, Akasaka H, Ueda C, et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol. 2000;18:510 518.

(24.) Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.

(25.) de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation oftissuemicroarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. JClin Oncol. 2007;25:805-812.

(26.) Chu PG, Loera S, Huang Q, Weiss LM. Lineage determination of CD20B-Cell neoplasms: an immunohistochemical study. Am J Clin Pathol. 2006;126: 534-544.

(27.) Rudiger T, Jaffe ES, Delsol G, et al. Workshop reporton Hodgkin's disease and related diseases ('grey zone' lymphoma). Ann Oncol. 1998;9:S31-S8.

(28.) Browne P, Petrosyan K, Hernandez A, Chan JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol. 2003;120:767-777.

(29.) Torlakovic E, Torlakovic G, Nguyen PL, Brunning RD, Delabie J. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am JSurgPathol. 2002;26:1343-1350.

(30.) Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by im munocytochemistry. Blood. 2002;99:409-426.

(31.) Vassallo J, Lamant L, Brugieres L, et al. ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: reportof10 cases. Am J SurgPathol. 2006;30:223-229.

(32.) Brauninger A, Wacker HH, Rajewsky K, Kuppers R, Hansmann ML. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res. 2003;63:1644-1651.

(33.) Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominantHodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97:496-501.

(34.) Yao X, Teruya-Feldstein J, Raffeld M, Sorbara L, Jaffe ES. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14:105-110.

(35.) Quintanilla-Martinez L, Preffer F, Rubin D, Ferry JA, Harris NL. CD20 + T-cell lymphoma: neoplastic transformation of a normal T-cell subset. Am JClin Pathol. 1994;102:483-489.

(36.) Lynch EF, Jones PA, Swerdlow SH. CD43 and CD5 antibodies define four normal and neoplastic B-cell subsets: a three-color flow cytometric study. Cytom etry. 1995;22:223-231.

(37.) Youinou P, Pers JO, Jamin C, Lydyard PM. CD5-positive B cells at the crossroads of B cell malignancy and nonorgan-specific autoimmunity. Pathol Biol (Paris). 2000;48:574-576.

(38.) Dorfman DM, Shahsafaei A. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections. Mod Pathol. 1997;10:859-863.

(39.) Arber DA, Weiss LM. CD43: a review. Appl/mmunohistochem. 1993;1: 88-96.

(40.) Arber DA. CD10: a review. Appl/mmunohistochem. 1997;5:125-140.

(41.) Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852.

(42.) Cook JR, Craig FE, Swerdlow SH. Benign CD10-positiveT cells in reactive lymphoid proliferations and B-cell lymphomas. Mod Pathol. 2003;16:879-885.

(43.) Cook JR, Craig FE, Swerdlow SH. Bcl-2 quantitation by multicolor flow cytometry in neoplastic and benign CD10 positive and CD10 negative B-lym phocytes. Mod Pathol. 2002;15:989.

(44.) Strauchen JA, Miller LK. Lymphoid progenitor cells in human tonsils. /nt J SurgPathol. 2003;11:21-24.

(45.) Hyjek E, Chadburn A, Liu YF, Cesarman E, Knowles DM. BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus. Blood. 2001;97:270-276.

(46.) Utz GL, Swerdlow SH. Distinction of follicular hyperplasia from follicular lymphoma in B5-fixed tissues: comparison of MT2 and bcl-2 antibodies [see comments]. Hum Pathol. 1993;24:1 155-1 158.

(47.) Rushin JM, Riordan GP, Heaton RB, Sharpe RW, Cotelingam JD, Jaffe ES. Cytomegalovirus-infected cells express Leu-M1 antigen: a potential source ofdi agnostic error. Am JPathol. 1990;136:989-995.

(48.) Pellegrini W, Bresciani G, De Zorzi A, Marocolo D, Ungari M, Facchetti F. MMA monoclonal antibody is a superior anti-CD15 reagent for the diagnosis of classical Hodgkin's lymphoma? Haematologica. 2007;92:708-709.

(49.) Nam-Cha SH, Rondacor G, Sanchez-Verde L, et al. PD-1, a follicular Tcell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am JSurgPathol. 2008;32:1252-1257.

Christine F. Garcia, Steven H. Swerdlow

Accepted for publication October 16, 2008.

From the Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

The authors have no relevant financial interest in the products or companies described in this article.

This article is provided for educational purposes only and is not intended to suggest either a practice standard or the only acceptable pathway for diagnostic evaluation. The views presented reflect the authors' opinions. The application of these opinions to a particular medical situation must be guided by the informed medical judgment of the responsible pathologist(s) based on the individual circumstances presented by the patient. The College of American Pathologists has no responsibility for the content or application of the views expressed herein.

Reprints: Steven H. Swerdlow, MD, Division of Hematopathology, University of Pittsburgh Medical Center Presbyterian, Room G335, 200 Lothrop St, Pittsburgh, PA 15213 (e-mail: swerdlowsh@upmc.edu).
Table 1. Multipurpose Panel for the Evaluation of Suspected
Non-Hodgkin Lymphomas

Antigen     Major Normal Reactivity      Purpose

CD20        Most B cells, small          To identify B lineage in the
            subset of T cells            absence of any features to
                                         the contrary. Beware, some
                                         T-cell lymphomas are
                                         positive, (34, 35) and some
                                         B-cell lymphomas are
                                         very weakly positive
                                         (eg, CLL/SLL) or negative.
CD3         T cells and natural          To identify T or natural
            killer cells                 killer cell lineage in the
                                         absence of any features
                                         to the contrary; may be lost
                                         in some T-cell neoplasms.
CD5         T cells, small B-cell        To identify major [CD5.sup.+]
            subset (36)                  B-cell populations. (7, 37,
                                         38) Also should be positive
                                         in almost all normal T cells
                                         but negative in natural
                                         killer cells. [CD5.sup.-]
                                         [CD3.sup.+] populations
                                         need to be further pursued.
CD43        T cells, small B-cell        To identify major [CD43.sup.+]
            subset, some plasma cells    B-cell populations.
            and myeloid cells. (39)      Some would be less
                                         enthusiastic about the
                                         inclusion of CD43 in a panel
                                         such as this.
CD10        Most follicular/GC B         To identify [CD10.sup.+] B
            cells, subset of lym-        cells which, if mature,
            phoblasts, small subset      supports their GC origin, and
            of mature T cells,           assess their distribution (are
            neutrophils, and some        they restricted to GC?). Also
            epithelial cells. (40-42)    will identify [CD10.sup.+]
                                         T cells with generally
                                         crisper, more intense
                                         staining, the characteristic
                                         phenotype of the neoplastic
                                         cells in AILT. (43) Will also
                                         highlight subset of lym-
                                         phoblasts that can even be
                                         present in reactive
                                         hyperplasias. (44)
BCL6        Most GC B cells, small       To help identify GC B cells,
            T-cell subset, and some      particularly when CD10 is very
            other cells. (30) Weak       weak or negative and in
            staining may not have        algorithms used to further
            the same implications as     classify DLBCL. [CD10.sup.-],
            stronger staining. This      [BCL6.sup.+] GCs are not a
            is a less specific but       specific finding but are often
            more sensitive marker        found in MZL with follicular
            for GC cells.                colonization. ALCL and T-LBL
                                         are often positive. (30, 45)
BCL2        Many lymphoid cells but      Primary uses are to identify
            not many normal GC B         clearly abnormal positive GC,
            cells. (30, 46)              highlight potentially normal
                                         GC and aid in the differential
                                         diagnosis between DLBCL
                                         (variable) and BL (negative).
Cyclin D1   Normal lymphoid cells        To identify abnormal cyclin
            negative, some endothelial   D1-positive lymphoid or
            and histiocyte nuclei        plasma cells.
            positive that function
            as internal positive
            controls. (12, 30)

Abbreviations: AILT, angioimmunoblastic T-cell lymphoma; ALCL,
anaplastic large cell lymphoma; BL, Burkitt lymphoma; CLL/SLL,
chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL,
diffuse large B cell lymphoma; GC, germinal center; MZL, marginal
zone lymphoma; T-LBL, T-lymphoblastic leukemia/lymphoma.

Table 2. Basic Hodgkin Lymphoma Panel

                                       Neoplastic Cell Phenotype

          Normal Hematopoietic/
Antigen   Lymphoid Reactivity                    cHL

CD20      B cells, few T cells       Most cases negative; some cases
                                     positive, usually with staining
                                     of only a subset of R-S
CD3       T cells, NK cells          Only rarely positive
CD15      Granulocytes, some         Most (~85%) but not all cases
          histiocytes, some          positive (48)
          epithelial cells and
          carcinomas, CMV-infected
          cells (47)
CD30      Activated lymphoid cells   Positive
LCA       Leukocytes                 Negative
EMA       Some plasma cells          Only rarely positive

               Neoplastic Cell Phenotype

Antigen    NLPHL                         B-NHL

CD20      Positive                     Most cases
                                       positive
CD3       Negative                     Negative
CD15      Negative                     Most cases
                                       negative
CD30      Usually negative;            Often neg-
          occasionally                 ative
          positive; nonneoplastic
          positive cells may be seen
LCA       Positive                     Usually
                                       positive
EMA       Some positive                Usually
                                       negative

Abbreviations: B-NHL, B-cell non-Hodgkin lymphoma; cHL, classical
Hodgkin lymphoma; CMV, cytomegalovirus; EMA, epithelial membrane
antigen; LCA, leukocyte commmon antigen; NLPHL, nodular lymphocyte
predominant Hodgkin lymphoma; R-S, Reed-Sternberg cells.

Table 3. Take-Home Messages

Establish a differential diagnosis based on clinical and morphologic
  evaluation prior to ordering additional ancillary studies on
  paraffin-embedded tissues.

Interpret the stains with your differential diagnosis in mind--do
  not interpret the stains blindly (simply with a long list of
  antibodies and 1 +,2+,3+ designations), and do not interpret
  them wildly (know the implications of your observations).

Use panels of immunohistochemical stains, and be sure that
  everything adds up--discrepant staining patterns may be an
  important clue to a specific diagnosis, to problems with a
  given stain, or to problems with your proposed diagnosis

Table 4. Diagnostically Useful Antigens Detectable Using
Paraffin-Reactive Antibodies

Cell Type Antigens Detectable

B cells                          CD20, CD79a, CD22, PAX5(BSAP)
Markers useful for defining      CD10, BCL6, CD23, BCL2, CD5,
  B-cell subsets and/or          CD43, cyclin D1, IRF4/MUM1
  classifying B-cell lymphomas
T cells (all but CD5 also on     CD2, CD3, CD5, CD7
NK cells)
T-cell subsets                   CD4, CD8, CD56, CD57,
                                 TIA-1, granzyme-B, [beta]-F1,
                                 CXCL13, PD-1
NK-associated                    CD56, CD57
Hodgkin lymphoma-associated      CD30 and CD15 (classical), J
                                 chain (NLPHL), Oct2 and/or
                                 Bob-1 absent or minimal (classical)
Other markers used in            CD45 (LCA), CD30, EMA, ALK-1,
lymphoma diagnosis               clusterin, Ki-67
Plasma cells                     CD138, VS38c, [kappa], [lambda],
                                 IgG, IgM, IgA, IgD
Follicular dendritic cells       CD21, CD23 (subset), CD35, clusterin
Other dendritic cells            CD1a (LC), Langerin (LC), S100 (LC and
                                 IDC), CD123 (plasmacytoid dendritic
                                 cells as well as some AML, HCL)
Immature/precursor cells         CD34, CD99 (not specific), TdT, CD1a
                                 (thymocytes), CD117 (mostly myeloid)
Myeloid/monocytic                Lysozyme, myeloperoxidase, CD33,
                                 neutrophil elastase, CD117, CD68,
                                 CD163, CD14, glycophorin (erythroid),
                                 VWF/FVIIIRA (megakaryocytes), CD42b
                                 (megakaryocytes)
Mast cells                       Tryptase, CD117 (strongly positive)
Viral markers                    EBV- LMP-1 (plus EBER ISH), HHV-8
                                 (KSHV), CMV, other

Abbreviations: AML, acute myeloid leukemia; CMV, cytomegalovirus; EBV,
Epstein-Barr virus; HCL, hairy cell leukemia; HHV-8, human herpesvirus
8; IDC, interdigitating dendritic cells; ISH, in situ hybridization;
KSHV, Kaposi sarcoma herpesvirus; LC, Langerhans cells; mega,
megakaryocytes; NK, natural killer; NLPHL, nodular
lymphocyte-predominant Hodgkin lymphoma; VWF/FVIIIRA, vonWillebrand
factor/factor VIII--related antigen.
Gale Copyright: Copyright 2009 Gale, Cengage Learning. All rights reserved.